You just read:

Armetheon Reaches Agreement with FDA to Conduct a 1000 Patient Single Phase 3 Study Prior to NDA Filing for its Novel Oral Anticoagulant Tecarfarin

News provided by

Armetheon, Inc.

Feb 09, 2017, 08:00 ET